- Home
- IMAB vs LIEN Comparison
IMAB vs LIEN Comparison
Compare IMAB & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- LIEN
- Stock Information
- Founded
- IMAB 2014
- LIEN 2021
- Country
- IMAB United States
- LIEN United States
- Employees
- IMAB N/A
- LIEN N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- LIEN
- Sector
- IMAB Health Care
- LIEN
- Exchange
- IMAB Nasdaq
- LIEN NYSE
- Market Cap
- IMAB 200.9M
- LIEN 234.6M
- IPO Year
- IMAB 2020
- LIEN 2022
- Fundamental
- Price
- IMAB $2.29
- LIEN $10.22
- Analyst Decision
- IMAB Strong Buy
- LIEN Buy
- Analyst Count
- IMAB 2
- LIEN 2
- Target Price
- IMAB $6.00
- LIEN N/A
- AVG Volume (30 Days)
- IMAB 1.0M
- LIEN 61.5K
- Earning Date
- IMAB 05-15-2025
- LIEN 08-07-2025
- Dividend Yield
- IMAB N/A
- LIEN 13.46%
- EPS Growth
- IMAB N/A
- LIEN 30.25
- EPS
- IMAB N/A
- LIEN 1.15
- Revenue
- IMAB N/A
- LIEN $30,828,508.00
- Revenue This Year
- IMAB N/A
- LIEN $154.46
- Revenue Next Year
- IMAB N/A
- LIEN $10.64
- P/E Ratio
- IMAB N/A
- LIEN $8.76
- Revenue Growth
- IMAB N/A
- LIEN 151.96
- 52 Week Low
- IMAB $0.60
- LIEN $9.70
- 52 Week High
- IMAB $3.08
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- IMAB 53.66
- LIEN N/A
- Support Level
- IMAB $2.00
- LIEN N/A
- Resistance Level
- IMAB $2.95
- LIEN N/A
- Average True Range (ATR)
- IMAB 0.35
- LIEN 0.00
- MACD
- IMAB -0.07
- LIEN 0.00
- Stochastic Oscillator
- IMAB 30.53
- LIEN 0.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.